Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BBIO) Stock Overview

Explore BridgeBio Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.

BBIO●NASDAQ
HealthcareBiotechnology
$82.37
$2.41(3.02%)
U.S. Market is Open · 14:25

BridgeBio Pharma, Inc. (BBIO)

Meyka AI Score

Z

Key Financials

Market Cap16.1B
P/E Ratio-21.85
EPS (TTM)$-3.74
ROE0.36%
Fundamental Analysis

AI Price Forecasts

1 Month$84.75
3 Months$90.11
1 Year Target$91.33

BBIO Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of BridgeBio Pharma, Inc. (NASDAQ: BBIO) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, BridgeBio Pharma, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of BBIO on the NASDAQ shows an RSI of 54.88, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $91.33 for the NASDAQ listing.

Key metrics behind BridgeBio Pharma, Inc.'s NASDAQ-traded stock include a P/E ratio of -21.85 and a market capitalization of 16.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BBIO on the NASDAQ.

Price Performance (NASDAQ: BBIO)

1-Day Change
2.64%
5-Day Change
2.51%
1-Month Change
5.56%
3-Month Change
18.96%
6-Month Change
9.15%
Year-to-Date (YTD) Change
7.30%
1-Year Change
71.87%
3-Year Change
162.62%
5-Year Change
55.35%
All-Time (Max) Change
197.89%

Contact Information

https://www.bridgebio.com
650 391 9740
3160 Porter Drive, Palo Alto, CA, 94301

Company Facts

8,390 Employees
IPO DateJun 27, 2019
CountryUS
Actively Trading

Frequently Asked Questions